TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02938624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV single dose
Description: Pembrolizumab 200 mg IV single dose, 21 days later surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV twice interval 21 days
Description: Pembrolizumab 200 mg IV twice interval 21 days, 21 days later surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
Description: Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 100 mg I.V single dose
Description: Pembrolizumab 100 mg I.V single dose, surgery after 21 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of tumor
Description: Surgical resection of tumor by any of the acceptable procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of tumor
Description: Surgical resection of tumor by any of the acceptable procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of tumor
Description: Surgical resection of tumor by any of the acceptable procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of tumor
Description: Surgical resection of tumor by any of the acceptable procedures
Study: NCT04053010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin-IPV and DTaP
Description: Sabin-IPV +DTaP at the age of 3/4/5 months old respectively

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin-IPV
Description: Sabin-IPV only at the age of 3/4/5 months old respectively

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP
Description: DTaP only at the age of 3/4/5 months old respectively
Study: NCT00082017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCN-01 (7-hydroxystaurosporine)
Description: UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 28 days.~UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCN-01 (7-hydroxystaurosporine)
Description: UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 28 days.~UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 21 days.
Study: NCT03425357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Load Exercises
Description: All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition).
Study: NCT01914211

Intervention type: DRUG
Intervention: Tranexamic Acid
Description: 100mg/kg prior to incision, 100mg/kg on CPB and 100mg/kg after reversal of heparin with protamine.

Intervention type: PROCEDURE
Intervention: Acute Normovolemic Hemodilution
Description: Draw 20 mL/kg (up to 5Kg) of blood from patient and replace with washed PRBCs at 10-20mL/kg. (If \> 5Kg draw 20% of circulating blood volume without PRBC replacement)
Study: NCT03085238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M-Trap
Description: Device(s) will be surgically implanted in the peritoneal cavity. Up to three (3) M-Trap devices will be surgically implanted via laparotomy in the right and left paracolic (pelvic) gutters and behind segment 6 of the liver within the peritoneal cavity of the patient at the time of surgical resection. Patients will receive standard platinum-based chemotherapy. If the cancer is diagnosed to have recurred, M-Trap devices with captured tumor cells will be removed via minimally invasive surgery (laparoscopy).
Study: NCT04660318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote photoplethysmography for physiological parameters
Description: physiological parameters will be acquired using the Remote photoplethysmography software simultaneously for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)

Intervention type: DEVICE
Group type: OTHER
Intervention: standard acquisition system for physiological parameters
Description: physiological parameters will be acquired using the standard acquisition system for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
Study: NCT02119221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: Intravenous infusion of 12 mg copanlisib labeled with 2.76 MBq (75 μCi) of \[14C\]
Study: NCT04690725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3525
Description: TQB3525 is an orally bioavailable, potent, class I kinase inhibitors of PI3Ka and PI3Kd.
Study: NCT02042300

Intervention type: DEVICE
Intervention: XIENCE Xpedition/Alpine/Sierra
Study: NCT03843424

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eSOC program
Description: American Medical Association (AMA) recommended staged approach to childhood obesity screening and counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eSOC program
Description: American Medical Association (AMA) recommended staged approach to childhood obesity screening and counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FBT program
Description: An intensive,comprehensive, behavioral intervention aligned with the US Preventive Services Task Force recommendations for childhood obesity screening and counseling.
Study: NCT05152654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tacker
Description: metallic staples used to fix the mesh
Study: NCT00880386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 50 mg Losartan will be taken daily by subjects for 24 weeks
Study: NCT01695330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib
Description: Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.
Study: NCT02889835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supreme Universal Restorative

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supreme Flowable Restorative

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bulk Fill Flowable Restorative
Study: NCT02666898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA101
Description: Part 1 :6 cycles~Obinutuzumab/GA101:~First cycle:~D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v~Cycle 2 to 6 (every 28 days) :~D1 of every cycle: 1000 mg i.v PART 2 4 cycles~-patients have BM MRD \>10-4 or PR: Cycle 1 to 4 Obitinuzumab/GA101: 1000 mg i.v on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Part 1 :6 cycles~Cycle 2 to 6 (every 28 days) :Ibrutinib:~D3 Month 1 to Day 30 Month 15: 420mg daily PO PART 2:4 cycles~* patients in CR with BM MRD \< 10-4 : Ibrutinib alone 420mg daily~* patients with BM MRD \>10-4 whatever responses or PR :Cycle 1 to 4 Ibrutinib 420mg daily with Cyclophosphamide and Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: PART 2 :~patients with BM MRD \>10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: PART 2 :~patients with BM MRD \>10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days : Fludarabine : 40 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and cyclophosphamide
Study: NCT03344965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: olaparib tablets bid daily continuously on a 21 day cycle until progression, intolerable toxicity, consent withdrawn, patient noncompliance or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: olaparib tablets bid daily continuously on a 21 day cycle until progression, intolerable toxicity, consent withdrawn, patient noncompliance or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: olaparib tablets bid daily continuously on a 21 day cycle until progression, intolerable toxicity, consent withdrawn, patient noncompliance or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: olaparib tablets bid daily continuously on a 21 day cycle until progression, intolerable toxicity, consent withdrawn, patient noncompliance or death.
Study: NCT02898324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KiVa program
Description: KiVa program is an anti-bullying intervention developed in University of Turku, Finland. It is based on the participant role model, where bullying is seen as a group process focused on the bystanders' reactions to the bullying. This program includes universal and indicated actions. Universal actions include ten students lessons given by teachers where pupils learn the role of bystanders in the bullying process, how to increase empathy towards the victim, and safe strategies to supports victims. Indicated actions are delivered by a school team of three staff members, who handle acute cases of bullying.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KiVa program
Description: KiVa program is an anti-bullying intervention developed in University of Turku, Finland. It is based on the participant role model, where bullying is seen as a group process focused on the bystanders' reactions to the bullying. This program includes universal and indicated actions. Universal actions include ten students lessons given by teachers where pupils learn the role of bystanders in the bullying process, how to increase empathy towards the victim, and safe strategies to supports victims. Indicated actions are delivered by a school team of three staff members, who handle acute cases of bullying.
Study: NCT04026412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Specified dose on specified days
Study: NCT03784118

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Ultrasonography is used to evaluate the change in artery size after arterial catheterization and to assess the complication in children

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: perfusion index
Description: measurement of perfusion index immediately after arterial catheterization until surgery end, in arterial catheterization site and contralateral site.
Study: NCT02433041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol 0.005mg/kg at induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol + Ketamine
Description: Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution (NaCl 0.9%)
Description: Placebo being used in one of the four groups
Study: NCT03435224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00012
Description: Noninvasive pulse oximeter sensor
Study: NCT02429310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revitive IX
Description: This is a neuromuscular electrical stimulation device
Study: NCT01729052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study: NCT03921970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESP block (Group ESP)
Description: Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
Study: NCT03399903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentasa vs Align
Description: We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentasa vs Align
Description: We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.
Study: NCT02002533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy
Description: Undergo BBT intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Undergo BBT intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Undergo HEAL

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Intervention
Description: Undergo HEAL
Study: NCT03964467

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: see arm/group descriptions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: see arm/group descriptions
Study: NCT05669898

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain scores (numerical rating scale at rest and motion): will be assessed with numerical rating scale at both rest and motion on both knees.
Description: Pain scores will be assessed with numerical rating scale at both rest and motion on both knees.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain scores (numerical rating scale at rest and motion): will be assessed with numerical rating scale at both rest and motion on both knees.
Description: Pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
Study: NCT01002547

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E-placebo
Description: Placebo of vitamin E will be given to arm 3.
Study: NCT05669898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale
Description: For the functional assessment both before and after TKA surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale
Description: For the functional assessment both before and after TKA surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation physiotherapy
Description: Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of both knees.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation physiotherapy
Description: Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of both knees.
Study: NCT03240523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Orally, 2 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Orally, 2 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Orally, 2 mg, once daily
Study: NCT00750412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeenScreen Program
Description: Adolescents who are randomized into the TeenScreen program and their parent/guardian will receive post-screening information, a facilitated referral, and case management services from a research social worker.
Study: NCT05642624

Intervention type: DRUG
Intervention: Deoxycholic acid amphotericin B
Description: Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.

Intervention type: DRUG
Intervention: Deoxycholic acid amphotericin B
Description: Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.
Study: NCT01101659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: 500 mg as 20 mL of oral suspension

Intervention type: DRUG
Group type: OTHER
Intervention: normal saline
Description: single dose

Intervention type: DRUG
Group type: OTHER
Intervention: ketamine
Description: 20 mL of oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study: NCT02900417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: All the patients will receive sitagliptin 100mg daily
Study: NCT03415347

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abscess de-roofing and curettage
Description: Abscess de-roofing and curettage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abscess wide local excision
Description: Abscess wide local excision
Study: NCT03130816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic cord blood transplantation
Description: UCB with total nucleated cell count ≤ 7x108/kg will be used for this clinical trial. Suitable UCB (i.e., containing total nucleated cell count ≥2x107/kg with three or less mismatch among HLA-A, -B, and -DR) will be selected. This criterion was selected upon the rationale that even though minimal HLA mismatch is preferred, prior studies indicate significant effects of UCB therapy for patients with 3 HLA mismatches.
Study: NCT03498885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low ligation
Description: Left colic artery (LCA) is identified, Tie the sigmoid artery and superior rectal artery, Apical lymph node dissection with the left colic artery preservation is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High ligation
Description: The IMA is ligated and divided at 2 cm from its origin. Apicallymph nodes dissection is performed.
Study: NCT00770640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and insulin
Description: Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
Study: NCT02225327

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad alone
Description: Fluad

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad and PPV23 on the different arms
Description: Fluad and Prodiax

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad and PPV23 on the same arm
Description: Fluad and Prodiax

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23 alone
Description: Prodiax
Study: NCT02079636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV
Study: NCT04220333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mandalas of Emotions
Description: Application of mandalas during 15 minutes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants were requested to lie down, relax and pay attention to your breath.
Study: NCT03066245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-PLGA
Description: Bone marrow derived MSC seeded on biodegradable PLGA, supplemented with PL.
Study: NCT00835627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: flexible dose sertraline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-ip
Description: cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual 1 hour therapy sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined (sertraline + CBT-ip)
Description: flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12, individual 1 hour therapy sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: community care, treatment as usual: routine follow up with existing providers